Fig. 2.
Kaplan-Meier survival curves for 174 myeloma patients.
The curves are separated by: (A) “high” syndecan-1 levels (≥ 1170 units/mL, n = 58, median survival 20 months) versus (B) “low” syndecan-1 levels (< 1170 units/mL, n = 116, median survival 43 months). Open circles represent censored patients. The survival difference was highly significant (P = .0001).